RAD52 and lung carcinoma: In the case of rs3748523 (RAD52), lung cancer patients treated with an etoposide-cis/carboplatin regimen showed a higher overall survival (OS) in the study population (CC vs. CG + GG: hazard ratio [HR] = 0.78, 95% CI = 0.10–5.9, p = 0.82) adjusted for age, sex and pack-years of smoking using a multivariate Cox regression model but is not statistically significant.